0001213900-24-052167.txt : 20240612 0001213900-24-052167.hdr.sgml : 20240612 20240612172643 ACCESSION NUMBER: 0001213900-24-052167 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240611 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240612 DATE AS OF CHANGE: 20240612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 60 DEGREES PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001946563 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452406880 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41719 FILM NUMBER: 241039396 BUSINESS ADDRESS: STREET 1: 1025 CONNECTICUT AVENUE NW STREET 2: SUITE 1000 CITY: WASHINGTON STATE: DC ZIP: 20036 BUSINESS PHONE: 202-327-5422 MAIL ADDRESS: STREET 1: 1025 CONNECTICUT AVENUE NW STREET 2: SUITE 1000 CITY: WASHINGTON STATE: DC ZIP: 20036 8-K 1 ea020775201-8k_60degrees.htm CURRENT REPORT
false 0001946563 DC 0001946563 2024-06-11 2024-06-11 0001946563 SXTP:CommonStockParValue0.0001PerShareMember 2024-06-11 2024-06-11 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2024-06-11 2024-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):

June 11, 2024

 

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41719   45-2406880
(State or other jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification Number)

 

1025 Connecticut Avenue NW Suite 1000,
Washington, D.C.		   20036
(Address of registrant’s principal executive office)   (Zip code)

 

(202) 327-5422

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.0001 per share   SXTP   The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock   SXTPW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01. Other Events.

 

On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company received U.S. Food and Drug Administration orphan drug designation for tafenoquine for treatment of patients with acute babesiosis. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are being filed herewith:

 

Exhibit No.   Description
99.1   Press Release of 60 Degrees Pharmaceuticals, Inc. dated as of June 11, 2024.
104     Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  60 DEGREES PHARMACEUTICALS, INC.
   
Date: June 12, 2024 By: /s/ Geoffrey Dow
  Name: Geoffrey Dow
  Title: Chief Executive Officer and President

 

 

 

 EX-99.1 2 ea020775201ex99-1_60degrees.htm PRESS RELEASE OF 60 DEGREES PHARMACEUTICALS, INC. DATED AS OF JUNE 11, 2024.

Exhibit 99.1

 

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis

 

·With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees.

 

·60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients.

 

·FDA orphan drug designation is granted for therapeutic candidates that may prevent or treat a rare disease or condition, such as acute babesiosis.

 

WASHINGTON, June 11, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharmaceuticals”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S. Food and Drug Administration (“FDA”) has granted its investigational tafenoquine candidate orphan drug designation for the treatment of patients with acute babesiosis.

 

FDA orphan drug designation is granted for therapeutic candidates that may prevent or treat a rare disease or condition, such as acute babesiosis. Babesiosis is a steadily emerging, infectious disease transmitted by a microscopic parasite, Babesia, through the bite of the black-legged (deer) tick, the vector that spreads Lyme disease. Babesiosis may be life-threatening in elderly and immunosuppressed patients. Up to 10 percent of Lyme disease patients may be coinfected with Babesia. Therefore, up to 47,600 of the estimated 476,000 patients with new Lyme infections each year may be co-infected with Babesia.

 

“Results of recent animal studies of tafenoquine show exciting promise for the drug to have potential in human patients with acute babesiosis,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoff Dow, PhD. “The FDA granting tafenoquine orphan drug designation for acute babesiosis validates the growing need for an additional therapeutic option that infectious disease specialists can use in addressing this very serious, potentially life-threatening illness. We look forward to results of our clinical trial program in coming months and to the prospect of securing a secondary indication for tafenoquine in the area of acute babesiosis treatment.”

 

60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating patients who have acute babesiosis. Recruitment for the trial will begin on June 13, 2024, and will include at least 24 patients hospitalized with babesiosis. Additional recruitment sites at prominent university hospitals in the Northeast U.S. are also planned.

 

With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees.

 

 

 

About Tafenoquine

 

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for such an indication.

 

About the Study of Tafenoquine for Patients Hospitalized with Babesiosis

 

The study is a randomized, double-blind, placebo-controlled trial that will enroll patients at multiple sites in the Northeast U.S. and will compare the safety and efficacy of tafenoquine versus placebo in patients hospitalized for babesiosis with low risk for relapsing disease who will also be administered a standard-of-care antimicrobial regimen. The two main study endpoints will be the time to sustained clinical resolution of symptoms and the time to molecular cure as determined by an FDA-approved nucleic acid test. At least 24, and as many as 33 patients, will be recruited before an interim analysis is conducted. Sufficient enrollment capacity is planned to allow all study subjects to be recruited during the 2024 tick season (June to September) if caseload is high. The interim analysis will include both a test of significance, as well as size re-estimation to allow additional recruitment if required. The study will be conducted at three hospitals in the Northeast U.S. The efficacy and safety of 8-aminoquinolines, a class of drugs that includes tafenoquine and primaquine, for prevention and treatment of malaria is well documented. Several case reports of tafenoquine use for babesiosis indicate that the drug is already being used for this purpose in the practice of medicine in the U.S.

 

About ARAKODA® (tafenoquine)


Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, may offer potential advantages in less-frequent dosing for prophylaxis for malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. 

ARAKODA® (tafenoquine) Important Safety Information


ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older.

 

Contraindications


ARAKODA® should not be administered to:

 

  · Glucose-6-phosphate dehydrogenase (“G6PD”) deficiency or unknown G6PD status;

 

  · Breastfeeding by a lactating woman when the infant is found to be G6PD deficient; or if

 

  · G6PD status is unknown;

 

  · Patients with a history of psychotic disorders or current psychotic symptoms; or

 

  · Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA(R).

 

 

 

Warnings and Precautions 


Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis.
G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant’s G6PD status before breastfeeding begins.


Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur.
Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible.


Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy.


Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration.


Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase, motion sickness, insomnia, depression, abnormal dreams, and anxiety.


Drug Interactions
Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters.

Use in Specific Populations
Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®.
To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The full prescribing information of ARAKODA® is located here.

About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.

 

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

 

 

Cautionary Note Regarding Forward-Looking Statements


This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non- malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330

 

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
(310) 989-5666

 

 EX-101.SCH 3 sxtp-20240611.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 sxtp-20240611_def.xml XBRL DEFINITION FILE EX-101.LAB 5 sxtp-20240611_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.0001 per share Warrants, each warrant to purchase one share of Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 sxtp-20240611_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 image_002.jpg GRAPHIC begin 644 image_002.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 11, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 11, 2024
Entity File Number 001-41719
Entity Registrant Name 60 DEGREES PHARMACEUTICALS, INC.
Entity Central Index Key 0001946563
Entity Tax Identification Number 45-2406880
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1025 Connecticut Avenue NW Suite 1000
Entity Address, City or Town Washington
Entity Address, State or Province DC
Entity Address, Postal Zip Code 20036
City Area Code (202)
Local Phone Number 327-5422
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $0.0001 per share  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol SXTP
Security Exchange Name NASDAQ
Warrants, each warrant to purchase one share of Common Stock  
Title of 12(b) Security Warrants, each warrant to purchase one share of Common Stock
Trading Symbol SXTPW
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://60degreespharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince - ea020775201-8k_60degrees.htm 21 ea020775201-8k_60degrees.htm sxtp-20240611.xsd sxtp-20240611_def.xml sxtp-20240611_lab.xml sxtp-20240611_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea020775201-8k_60degrees.htm": { "nsprefix": "SXTP", "nsuri": "http://60degreespharmaceuticals.com/20240611", "dts": { "inline": { "local": [ "ea020775201-8k_60degrees.htm" ] }, "schema": { "local": [ "sxtp-20240611.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "sxtp-20240611_def.xml" ] }, "labelLink": { "local": [ "sxtp-20240611_lab.xml" ] }, "presentationLink": { "local": [ "sxtp-20240611_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 26 }, "report": { "R1": { "role": "http://60degreespharmaceuticals.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea020775201-8k_60degrees.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea020775201-8k_60degrees.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "auth_ref": [] }, "SXTP_CommonStockParValue0.0001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://60degreespharmaceuticals.com/20240611", "localname": "CommonStockParValue0.0001PerShareMember", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.0001 per share" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "SXTP_WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://60degreespharmaceuticals.com/20240611", "localname": "WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants, each warrant to purchase one share of Common Stock" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://60degreespharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001213900-24-052167-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-052167-xbrl.zip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ea020775201-8k_60degrees_htm.xml IDEA: XBRL DOCUMENT 0001946563 2024-06-11 2024-06-11 0001946563 SXTP:CommonStockParValue0.0001PerShareMember 2024-06-11 2024-06-11 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2024-06-11 2024-06-11 iso4217:USD shares iso4217:USD shares false 0001946563 DC 8-K 2024-06-11 60 DEGREES PHARMACEUTICALS, INC. DE 001-41719 45-2406880 1025 Connecticut Avenue NW Suite 1000 Washington 20036 (202) 327-5422 false false false false Common Stock, par value $0.0001 per share SXTP NASDAQ Warrants, each warrant to purchase one share of Common Stock SXTPW NASDAQ true false